Penumbra has enrolled the first patient in STORM-PE, a randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash for the treatment of pulmonary embolism – PE -. In partnership with PERT Consortium, a multi-disciplinary group dedicated to improving the care of patients with PE, the STORM-PE trial aims to advance the understanding of the role of computer assisted vacuum thrombectomy – CAVT – in the management of acute PE, with a goal of improving the outcomes for patients with this life-threatening condition. STORM-PE will enroll up to 100 participants at up to 20 sites. Penumbra’s Lightning Flash can be used to remove emboli and thrombi from vessels of the peripheral arterial and venous systems and can be used for the treatment of PE.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PEN: